Hikma Pharmaceuticals (LSE:HIK) COGS-to-Revenue : 0.53 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals COGS-to-Revenue?

Hikma Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was £611 Mil. Its Revenue for the six months ended in Dec. 2023 was £1,144 Mil.

Hikma Pharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hikma Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was 46.62%.

Hikma Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Hikma Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals COGS-to-Revenue Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.51

0.49

0.51

0.52

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.49	0.50	0.52	0.50	0.53

Hikma Pharmaceuticals COGS-to-Revenue Calculation

Hikma Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1173.15	/	2271.25
	=	0.52

Hikma Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	610.67	/	1143.92
	=	0.53

Hikma Pharmaceuticals (LSE:HIK) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hikma Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	610.67 / 1143.92
	=	46.62 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hikma Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines